ReviewVirchows Archiv : an international journal of pathology2008
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
Review in Virchows Archiv : an international journal of pathology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 123 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 1 synthesis or guideline pooled it, 290 citations in OpenAlex.
- RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data.Biomarkers in medicine · 2017Pooled it
- Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.Molecular oncology · 2017Trial
- Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer.Molecular medicine (Cambridge, Mass.) · 2013Trial
- Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.Annals of surgery · 2011Trial
- KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Trial
- Therapy optimization in metastatic colorectal cancer guided by discordant KRAS mutation status between primary and metachronous recurrent lesions: a precision oncology case report.International journal of surgery case reports · 2026Article
- Experimental System Design and Modelling of EGFR Extracellular Domain and Its Mutant Binding to Antibody Interacting Partner.International journal of molecular sciences · 2025Article
- From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Prediction of anti-TNF therapy failure in ulcerative colitis patients by ensemble machine learning: A prospective study.Heliyon · 2023Article
- The ideal reporting ofPathologica · 2023Review
- TheCancers · 2023Article
- Middle East and North Africa Registry to Characterize Rate of RAS Testing Status in Newly Diagnosed Patients with Metastatic Colorectal Cancer.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Observational
- The Significance of External Quality Assessment Schemes for Molecular Testing in Clinical Laboratories.Cancers · 2022Review
- Review
- Review
- Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX.Scientific reports · 2021Article
- K-Ras Peptide Mimotope Induces Antigen Specific Th1 and B-Cell Immune Responses against G12A-Mutated K-Ras Antigen in Balb/c Mice.Vaccines · 2021Article
- The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization.Diagnostics (Basel, Switzerland) · 2021Review
- Article
- Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer.Oncology letters · 2020Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
18 authors at 13 institutions in 13 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with colorectal carcinoma. However, these therapies are effective only in a subset of patients. Activating mutations in the KRAS gene are found in 30-40% of colorectal tumors and are associated with poor response to anti-EGFR therapies. Thus, KRAS mutation status can predict which patient may or may not benefit from anti-EGFR therapy. Although many diagnostic tools have been developed for KRAS mutation analysis, validated methods and standardized testing procedures are lacking. This poses a challenge for the optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Here we review the molecular basis of EGFR-targeted therapies and the resistance to treatment conferred by KRAS mutations. We also present guideline recommendations and a proposal for a European quality assurance program to help ensure accuracy and proficiency in KRAS mutation testing across the European Union.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.